Skip to main content
. 2018 May 17;12(8):905–919. doi: 10.1093/ecco-jcc/jjy047

Figure 4.

Figure 4.

Exposure-adjusted incidence rate per 100 patient-years of respiratory tract infections [A], upper respiratory tract infection [B], and lower respiratory tract infection [C] in GEMINI 1, GEMINI 2, and combined GEMINI 1 and GEMINI 2 safety populations. Patients received vedolizumab every 4 weeks or every 8 weeks as maintenance therapy. Lower respiratory tract infection includes the MedDRA high-level term ‘lower respiratory tract and lung infection’. CD, Crohn’s disease; IR, exposure-adjusted incidence rate per 100 patient-years ([number of patients experiencing an adverse event of interest/total patient exposure time in years] × 100); LTS, long-term safety; UC, ulcerative colitis.